Objective: Traumatic brain injury is a major global public health problem for which specific therapeutic interventions are lacking. There is, therefore, a pressing need to identify innovative pathomechanism-based effective therapies for this condition. Thrombus formation in the cerebral microcirculation has been proposed to contribute to secondary brain damage by causing pericontusional ischemia, but previous studies have failed to harness this finding for therapeutic use. The aim of this study was to obtain preclinical evidence supporting the hypothesis that targeting factor XII prevents thrombus formation and has a beneficial effect on outcome after traumatic brain injury. Methods: We investigated the impact of genetic deficiency of factor XII and acute inhibition of activated factor XII with a single bolus injection of recombinant human albumin-fused infestin-4 (rHA-Infestin-4) on trauma-induced microvascular thrombus formation and the subsequent outcome in 2 mouse models of traumatic brain injury. Results: Our study showed that both genetic deficiency of factor XII and an inhibition of activated factor XII in mice minimize trauma-induced microvascular thrombus formation and improve outcome, as reflected by better motor function, reduced brain lesion volume, and diminished neurodegeneration. Administration of human factor XII in factor XII-deficient mice fully restored injury-induced microvascular thrombus formation and brain damage. Interpretation: The robust protective effect of rHA-Infestin-4 points to a novel treatment option that can decrease ischemic injury after traumatic brain injury without increasing bleeding tendencies. ANN NEUROL 2016;79:970-982 
As well as well-characterized injury processes, such as excitotoxicity, inflammation, and blood-brain barrier damage, thrombus formation in the cerebral microcirculation probably contributes to secondary brain damage by causing pericontusional ischemia and reducing regional cerebral blood flow. [4] [5] [6] [7] [8] [9] [10] In clinical TBI, intracerebral vessel occlusion with subsequent ischemia worsens the outcome. 8, 9, 11, 12 However, the potential use of conventional anticoagulants in patients with TBI is met with controversy, due to the increased risk of intracerebral hemorrhage. [13] [14] [15] [16] [17] [18] Previous studies from our laboratory have shown that both genetic deficiency and pharmacological inhibition of the coagulation factor XII (FXII), a protease that initiates the activation of the intrinsic coagulation cascade, protect mice from ischemic stroke without increasing bleeding tendencies. 19 ,20 Therefore, we tested whether deficiency or selective inhibition of FXII has a beneficial effect on trauma-induced microvascular thrombus formation, lesion volume, and functional outcome in TBI. In view of the heterogeneity of TBI, 3, 21 we used 2 complementary mouse models. A weight-drop closed-head injury model was used to induce concussionlike TBI with a prominent diffuse brain injury. 22, 23 In addition, cortical cryolesion was used to produce a strictly focal cortical brain injury without a contrecoup but with a standardized cortical lesion that enables reliable quantification of well-established pathophysiological readouts after TBI, such as lesion volume and neuronal apoptosis. 24 Our results show that genetic deficiency of FXII in mice results in less thrombus formation and a better outcome in experimental TBI, without increasing the risk of abnormal intracerebral hemorrhage. A similar effect is achieved when mice are treated once after TBI with a selective inhibitor of activated FXII (FXIIa). In alignment with these results, we also found intravascular platelet aggregates in brain tissue from a series of wellcharacterized patients with TBI. ) mice 26 were used in this study. Mice were housed in groups of 5 to 9, with free access to food and water and a 12-hour light/12-hour dark cycle. In this study, all experiments were approved by institutional and regulatory authorities and were conducted in accordance with the EU Directive 2010/63/EU, the US Public Health Service's Policy on Humane Care and Use of Laboratory Animals, and the ARRIVE criteria. 27 
Materials and Methods

Animals
Cortical Cryolesion Model
Cortical cryolesion was induced as described previously. 24 Briefly, 6-week-old mice were anesthetized with intraperitoneal injections of ketamine (0.1mg/g) and xylazine (0.005mg/g). After restraining the mouse head in a stereotactic frame (TSE Systems, Bad Homburg, Germany), surgery was performed on the right parietal cortex, the skull having been exposed through a scalp incision. A copper cylinder with a tip diameter of 2.5mm was filled with liquid nitrogen (21968C) and placed on the right parietal cortex (coordinates from the bregma: 1.5mm caudal, 1.5mm lateral) for 90 seconds. Sham-operated animals underwent the same surgical procedure without cooling of the copper cylinder.
Weight-Drop Model
Experimental closed-head injury was performed as previously described. 22, 23 Briefly, after the induction of isoflurane anesthesia, spontaneously breathing 10-to 16-week-old mice were placed in a stereotactic frame and the skulls were exposed by a midline longitudinal scalp incision. After identification of the impact area, a weight with a silicone-covered blunt tip was dropped with a final impact of 0.01J. Sham operation included anesthesia and exposure of the skull, but without weight-drop injury. The neurobehavioral status of the mice was assessed using the Neurological Severity Score (NSS), 22 ,23 a composite score including tasks on motor function, alertness, and physiological behavior, with lower scores indicating less deficit. Mice were evaluated 1 hours, 1 day, 3 days, and 7 days after weightdrop injury. The personnel who performed the functional assays were blinded to the experimental groups.
Pharmacological Treatment
One hour after induction of focal cryolesion or diffuse weightdrop injury, wild-type mice received a single intravenous injection of the specific FXII inhibitor recombinant human albumin-fused infestin-4 (rHA-Infestin-4; CSL Behring, Marburg, Germany) at a dose of 200mg/kg body weight. 20 Control animals received equal volumes of 0.9% sodium chloride (vehicle). Intravenous injection of 2lg/g body weight human FXII (hFXII; ADG412H; Sekisui Diagnostics, Lexington, MA), or an hFXII variant that cannot be activated due to modifications in the activation domain (hFXII-3xAla; CSL Limited, Parkville, Victoria, Australia), administered 1 hour after injury induction and continually every 72 hours, resulted in reconstitution of FXII 2/2 mice.
Determination of Lesion Size after Cortical Cryolesion
Twenty-four hours or 3 days after cryolesion, mice were sacrificed; the brains were quickly removed and cut into five 1-mmthick coronal sections using a mouse brain slice matrix (Harvard Apparatus, Holliston, MA). The slices were stained for 20 minutes at 378C with 2% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma-Aldrich, St Louis, MO) in phosphate-buffered saline to visualize the lesion. Lesion volumes were calculated by volumetry (ImageJ; National Institutes of Health, Bethesda, MD) in a blinded fashion.
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) was performed repeatedly 1 and 7 days after cryolesion on a 3T unit (Vision; Siemens Healthcare, Erlangen, Germany) under anesthesia with ketamine (0.1mg/g) and xylazine (0.005mg/g). The protocol included a coronal T2-weighted sequence (slice thickness 5 2mm) and a blood-sensitive coronal T2-weighted gradient-echo constructed interference in steady state (CISS) sequence (slice thickness 5 1mm). Lesion volumes were calculated by planimetry of the hyperintense area on high-resolution CISS images. CISS images were additionally examined for possible intracerebral hemorrhage.
To specifically analyze bleeding events after weight drop, MRI was performed repeatedly 1 and 7 days after weight drop, using a blood-sensitive coronal T2-weighted gradient-echo CISS sequence (slice thickness 5 1mm) and a susceptibility-weighted imaging sequence, which is particularly suitable for the detection of blood.
Laser Doppler Flowmetry
Laser Doppler flowmetry (Moor Instruments, Axminster, UK) was used to monitor regional cerebral blood flow over the right parietal cortex (impact area). Cerebral blood flow was measured serially at baseline (before injury induction) and 1 hour, 3 days, and 7 days after injury induction.
Histology and Immunohistochemistry
Cryoembedded mouse brains were cut into 10-lm-thick or 15-lm-thick slices (cortical cryolesion model and weight-drop model, respectively) using a cryostat (Leica Biosystems, Wetzlar, Germany 
Western Blot Analysis
Immunoreactivity for GPIb (anti-GPIb, 1:500, EMFRET Analytics) in lesioned cortices was detected by Western blot analysis as previously described. 24 Densitometric analysis of GPIb was performed in a blinded way using ImageJ software with b-actin (A5441, 1:500,000; Dianova) as loading control to normalize the levels of GPIb detected.
Spectrophotometric Hemoglobin Assay
The hemoglobin concentration in the brain parenchyma, which correlates with the extent of hemorrhage, was determined spectrophotometrically. 28 Twenty-four hours after trauma, animals were sacrificed and the brains were removed. The lesioned hemispheres were sonified for 60 seconds in 1.5ml ice-cooled water and afterward centrifuged at 48C for 30 minutes. Drabkin solution (1ml) was added to 250ll of the supernatant and incubated at room temperature for 15 minutes. The absorbance was measured at 540nm (MultiskanEX; Thermo Scientific, Waltham, MA).
Experimental Design
The numbers of animals necessary to detect a standardized effect size on lesion volumes 0.2 on day 1 after cortical cryolesion or NSS 0.2 on day 1 after weight-drop injury, respectively, were determined via a priori sample size calculation with the following assumptions: a 5 0.05, b 5 0.2, mean, and standard deviation (G*Power 3.0.10). Mice were randomly assigned to treatment groups (block randomization after cryolesion and, to achieve balanced groups, stratified randomization after weight-drop injury). To avoid bias, experiments were performed and analyzed in a blinded fashion.
Statistical Analysis
All results were expressed as mean 6 standard error of the mean except for the NSS scales, which are depicted as scatter plots, including median with the 25% percentile and the 75% percentile given in brackets in the text. For statistical analysis, the PrismGraph 5.0 software package (GraphPad, La Jolla, CA) was used. Data were tested for Gaussian distribution with the Kolmogorov-Smirnov test and, in the case of measuring the effects of 2 factors simultaneously, analyzed by 2-way analysis of variance (ANOVA) with post hoc Bonferroni correction for multivariate analyses or, in the case of nonparametric data (NSS), the Kruskal-Wallis test with post hoc Dunn correction. In the case of measuring the effect of 1 factor, 1-way ANOVA with post hoc Bonferroni correction was applied. If only 2 groups were compared, an unpaired, 2-tailed Student t test was performed. Probability values < 0.05 were considered to be statistically significant.
Results
Microvascular Thrombosis Is a Common Pathological Feature in TBI in Humans and Mice
First, we analyzed 20 human brain samples (Table 1) obtained from patients with TBI or control patients, and found significantly more microvascular platelet accumulations in the brain tissue of TBI cases than in control cases (Fig 1, p < 0.01 ). Consequently, we tested whether similar pathophysiological changes can be detected in experimental TBI in mice using a weight-drop model resulting in a predominantly diffuse brain trauma. Intravascular accumulations of GPIbpositive platelets were found significantly more often in the brain tissue of wild-type mice subjected to weightdrop compared with sham-treated mice. In the purely focal brain cortical cryolesion, numerous occluded vessels and intravascular accumulations of GPIb-positive platelets were also found in the /hFXII mice (Fig 2B) . We consistently detected less intravascular GPIb-positive platelet accumulation in the brains of FXII 2/2 and FXII
2/2
/hFXII3xAla mice (see Fig 2A) . Furthermore, Western blot analyses confirmed that the number of platelets was significantly diminished in the brain tissue of FXII 2/2 mice (see Fig 2C) . Similar to weight-drop injury, fewer thrombus-occluded brain vessels (Fig 3A) , a decreased number of platelets in the brain tissue (see Fig 3B) , and less platelet accumulation in the brain vasculature (see Fig 3C) were detected 1 and 3 days after focal cryolesion in FXII 2/2 mice compared with wild-type mice. Consequently, we conclude that FXII contributes to microvascular thrombosis independently of the nature of TBI.
FXII Deficiency Results in a Better Outcome after TBI
To evaluate the pathological significance of reduced intracerebral thrombosis in FXII 2/2 mice, we next determined the impact of FXII deficiency on functional outcome after weight-drop injury. Intravascular thrombosis after experimental TBI in rodents increases within the first 3 days. 29 Accordingly, trauma severity at the early stages (1 hour and 1 day after injury induction) was comparable in all groups, whereas FXII 2/2 mice and
/hFXII-3xAla mice had recovered significantly /hFXII mice (n 5 5 per group; **p < 0.01, ***p < 0.001). The lower panel shows a representative hematoxylin and eosin staining from a mouse brain section of the lesioned hemisphere on day 7 after weight-drop injury with numerous small vessels that are occluded by a thrombus (arrows; scale bar represents 100lm). (C) Western blot analysis using a GPIb antibody confirms that platelets accumulate to a lesser extent in FXII 2/2 mice compared with WT controls. Bands were quantified by densitometry in relation to b-actin control. The right panel shows 2 representative blots of each group (n 5 5 per group; **p < 0.01, ***p < 0.001). AU 5 arbitrary units.
better than wild-type or FXII /hFXII-3xAla mice; Fig 4) . Importantly, the better neurological outcome in FXII We next evaluated the impact of FXII deficiency on cortical lesion volume and neurodegeneration on days 1 and 3 after cryolesion. In male mice, FXII deficiency resulted in significantly reduced lesion volumes on days 1 and 3, as assessed by TTC staining of brain sections ( Fig  5) . As gender might have a significant impact on the clinical outcome following TBI, 30 we subjected female mice to cryolesion. Similar to male mice, FXII deficiency in female mice resulted in significantly smaller brain lesions on days 1 and 3 compared with wild-type mice. These observations were corroborated by studies using brain MRI, showing that FXII deficiency resulted in sustained reduction in lesion size after focal brain injury. Reduction in lesion volume was accompanied by significantly diminished neuronal apoptosis in FXII 2/2 mice on day 1 after cryolesion compared with control mice. An even more pronounced difference in the number of apoptotic cells was observed on day 3 after cryolesion.
Pharmacological Inhibition of FXIIa Results in Reduced Microvascular Thrombosis and a Better Outcome after TBI
To test the efficacy of pharmacological FXIIa inhibition for the treatment of pathological thrombosis in TBI, we administered rHA-Infestin-4, a selective inhibitor of /hFXII mice (n 5 4 per group; *p < 0.05, ***p < 0.001; scale bar represents 50lm). FIGURE 4: Factor XII (FXII) deficiency improves functional outcome after weight-drop injury. FXII 2/2 and FXII 2/2 mice reconstituted with human FXII-3xAla (FXII 2/2 1 hFXII-3xAla) had a significantly lower Neurological Severity Score (NSS) than wild-type (WT) and FXII 2/2 mice reconstituted with hFXII (FXII 2/2 1 hFXII) on days 3 and 7 after diffuse brain trauma. At 1 hour (day 0) and 1 day after trauma, animals had similar neurological deficits (n 5 10-13 per group; *p < 0.05, **p < 0.01).
showed that fewer thrombi occluded cerebral microvessels in rHA-Infestin-4-treated mice compared with vehicle-treated mice in both TBI models ( Figs 6A, B and 7A, B) .
The diminished thrombus formation in rHAInfestin-4-treated mice was associated with better neurological outcome. Although the initial severity of neurological deficits (1 hour and day 1) after weight-drop injury was comparable between the treatment groups Fig 6C) . After cryolesion, lesion volume and neurodegeneration on days 1 and 3 were reduced in rHA-Infestin-4-treated mice compared with vehicle-treated mice. For both readouts, the protective effect of rHA-Infestin-4 was even more pronounced on day 3 than on day 1 after cryolesion (see Fig 7C, D) . In summary, pharmacological inhibition of FXIIa results in reduced microvascular thrombosis and a better outcome after experimental TBI.
FXII Deficiency or Inhibition Does Not Increase the Risk of Intracerebral Hemorrhage
To prove whether blockade of FXII activity may be associated with an increased risk for cerebral hemorrhage after brain trauma, we used repeated MRI monitoring on days 1 and 7 after weight-drop injury. These analyses using bleeding-sensitive MRI sequences detected no signs of hemorrhages in the contusioned brain parenchyma of FXII 2/2 mice ( Table 2 , Fig 8) . In contrast, bleedings were evident in the traumatized brain tissue of mice deficient for FXI, the primary substrate of FXIIa in the intrinsic coagulation cascade, which is in line with the observation that FXI 2/2 humans have a mild to moderate bleeding phenotype. 31 The FXI 2/2 mice also showed increased hemoglobin content in the lesioned brain hemispheres after cryolesion, whereas no increase was detected in the brain tissue of FXII 2/2 or wild-type mice treated with rHA-Infestin-4 compared with shamoperated control mice. In accordance, MRI hypointense areas in brain tissue, indicating intracerebral hemorrhage after focal cryolesion, were absent in both wild-type and FXII 2/2 mice (see Fig 5B) .
Discussion
In view of the heterogeneous nature of TBI, we used 2 complementary mouse models to show that specific inhibition of FXIIa improves outcome after TBI in mice by reducing intracerebral thrombosis, but without increasing the risk of abnormal hemorrhage. In patients with TBI, anticoagulant treatment is met with controversy. Some studies support a net beneficial effect of anticoagulation following TBI achieved by reducing the risk of thromboembolic events 13, 32 and improving outcome parameters, 16, 33 whereas other studies report a detrimental effect of anticoagulation 17 due to an increased risk of Calculating the thrombosis index from brain sections stained with hematoxylin and eosin on day 7 showed a highly significant decrease of occluded vessels in mice treated with rHA-Infestin-4 (n 5 5 per group; ***p < 0.001).
(B) Analysis of immunofluorescence staining using glycoprotein Ib (GPIb) and CD31 antibodies reveals marked reduction in intravascular platelet depositions on day 7 after injury induction in mice treated with rHA-Infestin-4 (n 5 4 per group; ***p < 0.001). (C) Mice treated with rHA-Infestin-4 had a significantly lower Neurological Severity Score (NSS) than vehicle-treated (Vehicle) mice on days 3 and 7 after brain trauma. At 1 hour (day 0) and 1 day after brain trauma, animals had similar neurological deficits (n 5 13 per group; *p < 0.05).
intracranial hemorrhage that also occurs frequently after TBI. In this context, FXII could be an interesting target for anticoagulant treatment that is devoid of hemorrhagic risk.
For decades, FXII has been considered to have no coagulation function in vivo. In recent years, however, it has been shown that FXII 2/2 mice are resistant to experimentally induced thrombosis 34, 35 and ischemic brain injury. 19 As deficiency of FXII is not associated with abnormal hemorrhaging from injury sites (hemostasis) either in patients or in animals, 19, 34 inhibition of activated FXII prevented arterial thrombosis and ischemic brain injury 20, 36 without affecting hemostasis. 20, 37 Our current study shows that FXII is a promising antithrombotic target for the acute treatment of TBI, without increasing the risk of intracranial hemorrhage. Our results confirm that thrombus formation in the cerebral microvasculature is a common pathological feature in TBI. We observed thrombus formation in the cerebral vessels of patients with TBI but not in control patients. A similar pattern of pathological thrombus formation in cerebral microvessels in human TBI was also detected in 2 experimental models of brain injury. When we evaluated the impact of FXII deficiency, we found mice by the administration of hFXII but not by the administration of the recombinant FXII variant hFXII3xAla, which does not possess procoagulant activity. This proves, for the first time, that activation of the intrinsic coagulation pathway by FXII plays a key role in posttraumatic cerebral thrombus formation. Interestingly, in thrombus formation on atherosclerotic plaques, the extrinsic coagulation pathway triggered by the release of tissue factor contributes to the initial thrombus generation, whereas activated FXII ensures stability of the thrombus in later phases. 38 Considering that TBI immediately results in massive release of tissue factor (as reviewed by Maegele 12 ), a similar scenario might apply during cerebral thrombus formation in TBI.
Cerebral thrombus formation in our study was associated with a reduction in pericontusional blood flow. This may contribute to secondary brain damage, as reported previously both in humans 9, 39, 40 and in experimental TBI. [5] [6] [7] 10, 29, [41] [42] [43] Low post-traumatic cerebral blood flow is a known predictor of worse outcome in pediatric severe TBI 44 and in adult diffuse TBI. 45 Prevention of pathological thrombus formation in the cerebral microcirculation in FXII 2/2 mice or after acute treatment with rHA-Infestin-4 was also associated with a better neurological outcome in the present study.
In conclusion, genetic deficiency or selective inhibition of FXII in mice results in less cerebral thrombus formation and a better outcome in experimental TBI, without increasing the risk of abnormal hemorrhaging.
Despite intensive research, specific therapeutic interventions are still lacking for TBI. Challenging existing pathophysiological concepts and exploring innovative ideas might overcome this roadblock. The pathophysiological role of microvascular thrombosis in TBI has been neglected by previous research in the TBI field even though the presence of occluded cerebral vessels in patients with TBI was reported 1995. 4 Our study confirms and extends the previous clinical findings in a larger, well-characterized patient cohort and provides preclinical evidence that microvascular thrombosis might contribute to secondary brain damage. Moreover, it was shown for the first time that targeting FXII prevents thrombus formation and has a beneficial effect on outcome after TBI, indicating that it might be a novel treatment option to decrease ischemic injury after TBI. 
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